Survival curves showed that patients with high levels of BCL9L had a significantly shorter survival period than those with a low expression of BCL9L, suggesting that BCL9L might serve as a promising indicator for predicting the prognosis of patients with BLCA (Figure S3D). Here, BCL9L is linked to bladder transitional cell carcinoma.